Duchenne Muscular Dystrophy (Genitourinary Disorders) – Drugs In Development, 2021
- Pages: 489
- Published: July 2021
- Report Code: GMDHC12875IDB
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy – Drugs In Development, 2021, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape.
Duchenne muscular dystrophy (DMD) is a genetic disorder that causes muscles to gradually weaken over time. Signs and symptoms of DMD include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking. Risk factors include gender and family history. Treatment includes steroid medication, respiratory therapy and surgery.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Duchenne Muscular Dystrophy – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 2, 5, 14, 10, 3, 68, 27 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 1, 2, 1, 12 and 2 molecules, respectively.
Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy (Genetic Disorders).
– The pipeline guide reviews pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies mentioned
4D Molecular Therapeutics Inc
AAVogen Inc
Alpha Anomeric
American CryoStem Corp
Anagenesis Biotechnologies SAS
Antisense Therapeutics Ltd
Astellas Gene Therapies
AUM LifeTech Inc
Autotac Bio Inc
Avidity Biosciences Inc
Axolo Pharma Inc
Bayer AG
Biogen Inc
BioIncept LLC
Bioleaders Corp
BioMarin Pharmaceutical Inc
Biophytis SA
Capricor Therapeutics Inc
Catabasis Pharmaceuticals Inc
Chengdu Fanxi Biopharma Co Ltd
Code Biotherapeutics Inc
Consortium.AI
Constant Therapeutics LLC
CRISPR Therapeutics AG
Cumberland Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
DepYmed Inc
DMD Therapeutics Inc
DTx Pharma Inc
Dyne Therapeutics Inc
Dystrogen Therapeutics SA
Edgewise Therapeutics Inc
Editas Medicine Inc
Eli Lilly and Co
Eloxx Pharmaceuticals Inc
Encell Co Ltd
Entrada Therapeutics Inc
Epirium Bio Inc
Evox Therapeutics Ltd
FibroGen Inc
FibroGenesis LLC
Fulcrum Therapeutics Inc
InnoBioscience LLC
Italfarmaco SpA
Ixchel Pharma LLC
J2H Biotech
Keros Therapeutics Inc
LambdaGen Therapeutics
Ludi Therapeutics
Milo Biotechnology LLC
Mitobridge Inc
Mitochon Pharmaceuticals Inc
MyoGene Bio LLC
Myos Inc
Myosana Therapeutics Inc
MyoTherix Inc
Nippon Shinyaku Co Ltd
OliPass Corporation
Oncotelic Inc
Pepgen Ltd
PeptiDream Inc
Pfizer Inc
Pharmaxis Ltd
PhaseBio Pharmaceuticals Inc
Pliant Therapeutics Inc
Progenitor Therapeutics Ltd
Prothelia Inc
PTC Therapeutics Inc
PYCTX Ltd
RASRx LLC
RegenxBio Inc
ReoStem LLC
Ridgeline Therapeutics LLC
Santhera Pharmaceuticals Holding AG
Sarcomed AB
Sarepta Therapeutics Inc
Satellos Bioscience Inc
Solid Biosciences Inc
Stealth BioTherapeutics Corp
SteroTherapeutics LLC
Sutura Therapeutics Ltd
Suzhou GenAssist Therapeutics Co Ltd
Taiho Pharmaceutical Co Ltd
Tivorsan Pharmaceuticals Inc
Tolerion Inc
Triplex Therapeutics Inc
UGISense AG
Ultragenyx Pharmaceutical Inc
Vertex Pharmaceuticals Inc
Vita Therapeutics Inc
Wave Life Sciences Ltd
Zata Pharmaceuticals Inc
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.